Julie Min Jeung Paik, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Spinal Fractures | 6 | 2022 | 689 | 2.680 |
Why?
|
Renal Insufficiency, Chronic | 8 | 2023 | 1994 | 1.570 |
Why?
|
Polypharmacy | 3 | 2021 | 276 | 1.500 |
Why?
|
Diabetic Nephropathies | 3 | 2022 | 1039 | 1.430 |
Why?
|
Hip Fractures | 3 | 2022 | 885 | 1.320 |
Why?
|
Geriatrics | 2 | 2022 | 375 | 1.240 |
Why?
|
Nephrology | 2 | 2019 | 240 | 1.170 |
Why?
|
Pharmacists | 3 | 2019 | 224 | 0.930 |
Why?
|
Diabetic Ketoacidosis | 2 | 2023 | 232 | 0.910 |
Why?
|
Kidney Failure, Chronic | 4 | 2021 | 2570 | 0.810 |
Why?
|
Hyperkalemia | 1 | 2022 | 210 | 0.770 |
Why?
|
Renal Dialysis | 6 | 2021 | 1749 | 0.740 |
Why?
|
International Classification of Diseases | 2 | 2021 | 853 | 0.730 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 4 | 2023 | 244 | 0.720 |
Why?
|
House Calls | 1 | 2020 | 146 | 0.720 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2022 | 245 | 0.710 |
Why?
|
Calcium | 4 | 2017 | 5832 | 0.650 |
Why?
|
Kidney | 5 | 2022 | 6910 | 0.630 |
Why?
|
Diabetes Mellitus, Type 2 | 9 | 2023 | 11008 | 0.620 |
Why?
|
Histamine H2 Antagonists | 1 | 2018 | 169 | 0.620 |
Why?
|
Proton Pump Inhibitors | 2 | 2018 | 478 | 0.610 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2016 | 79 | 0.600 |
Why?
|
Inappropriate Prescribing | 1 | 2018 | 210 | 0.580 |
Why?
|
Parathyroid Hormone | 3 | 2012 | 1819 | 0.570 |
Why?
|
Hypoglycemic Agents | 7 | 2023 | 2779 | 0.570 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 3385 | 0.570 |
Why?
|
Waist Circumference | 1 | 2019 | 900 | 0.560 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 128 | 0.560 |
Why?
|
Glomerulosclerosis, Focal Segmental | 2 | 2015 | 335 | 0.540 |
Why?
|
Wrist Injuries | 1 | 2017 | 195 | 0.530 |
Why?
|
Nephrotic Syndrome | 2 | 2015 | 392 | 0.520 |
Why?
|
Fractures, Bone | 4 | 2021 | 1884 | 0.500 |
Why?
|
Gout | 2 | 2017 | 535 | 0.490 |
Why?
|
Cardiovascular Diseases | 6 | 2023 | 14381 | 0.480 |
Why?
|
Hyponatremia | 1 | 2016 | 306 | 0.480 |
Why?
|
Patient Care | 1 | 2019 | 616 | 0.480 |
Why?
|
Osteoporotic Fractures | 1 | 2017 | 375 | 0.470 |
Why?
|
Body Mass Index | 4 | 2019 | 12507 | 0.460 |
Why?
|
Heart Failure | 4 | 2023 | 10185 | 0.440 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1675 | 0.430 |
Why?
|
Osteoporosis | 2 | 2021 | 1568 | 0.410 |
Why?
|
Hyperthyroidism | 1 | 2012 | 285 | 0.400 |
Why?
|
Dietary Supplements | 2 | 2014 | 3070 | 0.400 |
Why?
|
Medication Adherence | 2 | 2022 | 2034 | 0.370 |
Why?
|
Calcium, Dietary | 1 | 2012 | 524 | 0.370 |
Why?
|
Phosphorus | 1 | 2010 | 343 | 0.360 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2020 | 1726 | 0.330 |
Why?
|
Aged | 26 | 2022 | 162862 | 0.320 |
Why?
|
Bone Density | 2 | 2017 | 3425 | 0.300 |
Why?
|
Myocardial Infarction | 3 | 2022 | 11424 | 0.300 |
Why?
|
Glucocorticoids | 2 | 2015 | 2108 | 0.290 |
Why?
|
Frail Elderly | 2 | 2022 | 609 | 0.290 |
Why?
|
Cohort Studies | 15 | 2022 | 39891 | 0.290 |
Why?
|
Glomerular Filtration Rate | 3 | 2023 | 2105 | 0.270 |
Why?
|
Humans | 50 | 2023 | 717280 | 0.270 |
Why?
|
Bone Density Conservation Agents | 1 | 2012 | 796 | 0.270 |
Why?
|
Nutrition Surveys | 1 | 2011 | 1572 | 0.260 |
Why?
|
Geriatric Assessment | 3 | 2022 | 1319 | 0.260 |
Why?
|
Veterans | 4 | 2022 | 2337 | 0.260 |
Why?
|
Stroke | 3 | 2022 | 9510 | 0.260 |
Why?
|
Nurses | 2 | 2015 | 2382 | 0.260 |
Why?
|
Telemedicine | 1 | 2020 | 2624 | 0.250 |
Why?
|
Prospective Studies | 10 | 2020 | 51277 | 0.250 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2016 | 153 | 0.240 |
Why?
|
Algorithms | 2 | 2021 | 13716 | 0.240 |
Why?
|
Female | 34 | 2023 | 377934 | 0.230 |
Why?
|
Silicates | 1 | 2022 | 48 | 0.230 |
Why?
|
Pruritus | 2 | 2015 | 340 | 0.220 |
Why?
|
Hydromorphone | 1 | 2021 | 64 | 0.200 |
Why?
|
Snoring | 1 | 2022 | 185 | 0.200 |
Why?
|
Adult | 21 | 2023 | 212470 | 0.200 |
Why?
|
Risk Assessment | 6 | 2021 | 23543 | 0.190 |
Why?
|
Self Report | 3 | 2022 | 3429 | 0.190 |
Why?
|
Glucosides | 2 | 2021 | 374 | 0.190 |
Why?
|
Education, Pharmacy | 1 | 2019 | 30 | 0.190 |
Why?
|
Hypertension | 2 | 2016 | 8285 | 0.190 |
Why?
|
United States | 17 | 2022 | 67804 | 0.180 |
Why?
|
Hyperphosphatemia | 1 | 2019 | 45 | 0.180 |
Why?
|
Middle Aged | 23 | 2023 | 215054 | 0.180 |
Why?
|
Risk Factors | 13 | 2021 | 70863 | 0.180 |
Why?
|
Renal Insufficiency | 2 | 2023 | 805 | 0.180 |
Why?
|
Lithium | 1 | 2022 | 615 | 0.170 |
Why?
|
Cold Ischemia | 1 | 2018 | 59 | 0.170 |
Why?
|
Calcium Phosphates | 1 | 2019 | 177 | 0.170 |
Why?
|
Fentanyl | 1 | 2021 | 402 | 0.170 |
Why?
|
Incidence | 8 | 2018 | 20654 | 0.160 |
Why?
|
Injections, Subcutaneous | 1 | 2019 | 688 | 0.160 |
Why?
|
Vitamin A | 2 | 2011 | 626 | 0.160 |
Why?
|
Hearing | 1 | 2021 | 431 | 0.160 |
Why?
|
Benzhydryl Compounds | 2 | 2021 | 709 | 0.160 |
Why?
|
Chelating Agents | 1 | 2019 | 404 | 0.160 |
Why?
|
Vitamin D | 3 | 2018 | 3164 | 0.160 |
Why?
|
Prospective Payment System | 1 | 2018 | 135 | 0.160 |
Why?
|
Publication Bias | 1 | 2017 | 164 | 0.160 |
Why?
|
Pilot Projects | 2 | 2020 | 8068 | 0.150 |
Why?
|
Thrombotic Microangiopathies | 1 | 2018 | 125 | 0.150 |
Why?
|
Diphosphonates | 1 | 2021 | 627 | 0.150 |
Why?
|
Hyperparathyroidism | 1 | 2017 | 341 | 0.140 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3130 | 0.140 |
Why?
|
Proteinuria | 2 | 2015 | 630 | 0.140 |
Why?
|
Tissue and Organ Harvesting | 1 | 2018 | 363 | 0.140 |
Why?
|
Administration, Oral | 2 | 2021 | 3963 | 0.130 |
Why?
|
Medicare | 6 | 2022 | 5787 | 0.130 |
Why?
|
Male | 20 | 2023 | 351399 | 0.130 |
Why?
|
Polymers | 1 | 2022 | 1630 | 0.130 |
Why?
|
Hearing Loss | 1 | 2021 | 714 | 0.130 |
Why?
|
Body Size | 1 | 2017 | 467 | 0.130 |
Why?
|
Needs Assessment | 1 | 2020 | 1151 | 0.130 |
Why?
|
Atrial Fibrillation | 2 | 2022 | 4530 | 0.130 |
Why?
|
Drug Interactions | 1 | 2018 | 1454 | 0.130 |
Why?
|
Comorbidity | 2 | 2020 | 10452 | 0.120 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 13276 | 0.120 |
Why?
|
Suicide, Attempted | 1 | 2022 | 1156 | 0.120 |
Why?
|
Interviews as Topic | 1 | 2020 | 2599 | 0.120 |
Why?
|
Spine | 1 | 2020 | 1116 | 0.120 |
Why?
|
Interprofessional Relations | 1 | 2019 | 1020 | 0.120 |
Why?
|
Ultraviolet Rays | 1 | 2017 | 1073 | 0.110 |
Why?
|
Kidney Calculi | 1 | 2015 | 449 | 0.110 |
Why?
|
Transplantation Conditioning | 1 | 2018 | 1573 | 0.100 |
Why?
|
Hospitalization | 2 | 2022 | 9754 | 0.100 |
Why?
|
Mexican Americans | 1 | 2011 | 172 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2022 | 13613 | 0.100 |
Why?
|
Sex Factors | 2 | 2017 | 10661 | 0.100 |
Why?
|
Age Factors | 3 | 2019 | 18798 | 0.100 |
Why?
|
Uric Acid | 2 | 2016 | 740 | 0.100 |
Why?
|
Antihypertensive Agents | 2 | 2021 | 2067 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1891 | 0.090 |
Why?
|
Aspirin | 1 | 2021 | 3169 | 0.090 |
Why?
|
Pain Measurement | 1 | 2019 | 3513 | 0.090 |
Why?
|
Kidney Diseases | 1 | 2019 | 2131 | 0.080 |
Why?
|
Massachusetts | 1 | 2020 | 8749 | 0.080 |
Why?
|
Atherosclerosis | 1 | 2022 | 3262 | 0.080 |
Why?
|
Demography | 1 | 2011 | 1624 | 0.070 |
Why?
|
Age Distribution | 1 | 2012 | 2930 | 0.070 |
Why?
|
Forecasting | 1 | 2015 | 2948 | 0.070 |
Why?
|
Sleep | 1 | 2022 | 4222 | 0.070 |
Why?
|
Databases, Factual | 1 | 2021 | 7847 | 0.070 |
Why?
|
Health Surveys | 1 | 2016 | 4023 | 0.070 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15271 | 0.070 |
Why?
|
Aged, 80 and over | 2 | 2021 | 58528 | 0.070 |
Why?
|
Graft Rejection | 1 | 2018 | 4411 | 0.070 |
Why?
|
Diet | 2 | 2014 | 7565 | 0.070 |
Why?
|
Seasons | 1 | 2010 | 1431 | 0.060 |
Why?
|
Bipolar Disorder | 1 | 2022 | 5060 | 0.060 |
Why?
|
Depressive Disorder, Major | 1 | 2022 | 4474 | 0.060 |
Why?
|
Creatinine | 2 | 2023 | 1907 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3750 | 0.060 |
Why?
|
Risk | 1 | 2016 | 9773 | 0.060 |
Why?
|
Prevalence | 1 | 2020 | 14899 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2018 | 4141 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5028 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2022 | 72608 | 0.060 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2022 | 87 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12484 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14904 | 0.050 |
Why?
|
Time Factors | 2 | 2021 | 41094 | 0.050 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2021 | 62 | 0.050 |
Why?
|
Ultrasonography | 1 | 2015 | 5948 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12416 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 11276 | 0.050 |
Why?
|
Hydrochlorothiazide | 1 | 2021 | 109 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 7292 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5152 | 0.050 |
Why?
|
Audiometry | 1 | 2021 | 252 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2011 | 23409 | 0.050 |
Why?
|
Glucose | 2 | 2022 | 4303 | 0.050 |
Why?
|
Young Adult | 3 | 2021 | 56249 | 0.050 |
Why?
|
Life Style | 1 | 2011 | 3719 | 0.050 |
Why?
|
Exercise | 1 | 2016 | 5329 | 0.050 |
Why?
|
Health Status | 1 | 2012 | 3995 | 0.040 |
Why?
|
Coronary Disease | 1 | 2014 | 6127 | 0.040 |
Why?
|
Antimanic Agents | 1 | 2022 | 530 | 0.040 |
Why?
|
Sodium | 1 | 2022 | 1606 | 0.040 |
Why?
|
Pyridones | 1 | 2021 | 687 | 0.040 |
Why?
|
United States Department of Veterans Affairs | 1 | 2021 | 870 | 0.040 |
Why?
|
Maine | 1 | 2016 | 141 | 0.040 |
Why?
|
Adolescent | 2 | 2021 | 85143 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2015 | 39302 | 0.040 |
Why?
|
Furosemide | 1 | 2015 | 170 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2298 | 0.030 |
Why?
|
Suicidal Ideation | 1 | 2022 | 1114 | 0.030 |
Why?
|
Propensity Score | 1 | 2019 | 1744 | 0.030 |
Why?
|
Pyrazoles | 1 | 2021 | 1976 | 0.030 |
Why?
|
Calcinosis | 1 | 2019 | 1456 | 0.020 |
Why?
|
Peptides | 1 | 2022 | 4438 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 5038 | 0.020 |
Why?
|
Antipsychotic Agents | 1 | 2022 | 3071 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2022 | 11910 | 0.020 |
Why?
|
Graft Survival | 1 | 2018 | 3765 | 0.020 |
Why?
|
Anticoagulants | 1 | 2021 | 4374 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10542 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2021 | 62344 | 0.020 |
Why?
|
Registries | 1 | 2018 | 8095 | 0.010 |
Why?
|
Prognosis | 1 | 2023 | 29226 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2019 | 6313 | 0.010 |
Why?
|